MEINIAN

Who owns MEINIAN?

MEINIAN was owned by Cathay Capital through Cathay Capital Small Cap II (2010 vintage) from 2013 to 2015, exited via IPO.

Hand-verified · updated 2026-04-21

About MEINIAN

Meinian Onehealth is a Shanghai-headquartered preventive-healthcare group that operates one of China's largest networks of medical examination centers, providing general health checkups, disease screening and related services such as doctor referrals and traditional Chinese preventive-health offerings. It positions itself as the country's leading private preventive-healthcare provider, serving corporate and individual clients through self-owned and affiliated centers across the mainland. As of the end of September 2024 the group operated 608 medical examination centers across 296 cities, with a workforce of roughly 56,000 people including medical technicians and nursing staff. Its shares are listed on the Shenzhen Stock Exchange, and it reported revenue of about CNY 10.70 billion for 2024, with medical examination services making up the large majority of sales.

Ownership journey

Meinian Onehealth was founded in 2004 in Shanghai by Yu Rong, building a chain of physical-examination centers to serve China's growing demand for preventive health screening. In 2013 Cathay Capital took a stake in the business through its Cathay Capital Small Cap II fund, backing the group's checkup network during its expansion phase. Cathay Capital exited in 2015 when Meinian Onehealth achieved a public listing on the Shenzhen Stock Exchange, converting the private holding into listed equity. No further sponsor legs are recorded on this sheet after that listing.

Under PE ownership

During and after the investment period Meinian Onehealth pursued aggressive expansion of its examination-center footprint, growing from a few hundred outlets toward a national network that reached 608 centers across 296 cities by late 2024. The 2015 public listing gave the group access to capital markets to fund further build-out and acquisitions in China's fragmented medical-examination sector. Revenue scaled to roughly CNY 10.70 billion in 2024, with professional medical examination services accounting for the overwhelming share of net sales. The company also broadened its ambitions beyond core checkups, adding disease-screening and referral services and consolidating its position as China's largest private preventive-healthcare operator.